Last reviewed · How we verify
Slow Infusion of Rubidium-82
Rubidium-82 is a positron-emitting radioactive tracer that accumulates in myocardial tissue proportional to blood flow, allowing visualization of cardiac perfusion defects via PET imaging.
Rubidium-82 is a positron-emitting radioactive tracer that accumulates in myocardial tissue proportional to blood flow, allowing visualization of cardiac perfusion defects via PET imaging. Used for Myocardial perfusion imaging for detection of coronary artery disease, Assessment of myocardial viability in patients with coronary artery disease.
At a glance
| Generic name | Slow Infusion of Rubidium-82 |
|---|---|
| Also known as | 20 mls/min of Rubidium-82 |
| Sponsor | Ochsner Health System |
| Drug class | Positron emission tomography (PET) imaging agent |
| Target | Na+/K+-ATPase pump (potassium analog) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rubidium-82 is a potassium analog that is taken up by viable myocardial cells via Na+/K+-ATPase pumps. When infused slowly intravenously, it distributes to the heart in proportion to regional blood flow. The positron emissions are detected by PET cameras to create images showing areas of reduced perfusion (ischemia) versus normal perfusion, enabling assessment of coronary artery disease and myocardial viability.
Approved indications
- Myocardial perfusion imaging for detection of coronary artery disease
- Assessment of myocardial viability in patients with coronary artery disease
Common side effects
- Flushing
- Chest discomfort
- Dyspnea
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Slow Infusion of Rubidium-82 CI brief — competitive landscape report
- Slow Infusion of Rubidium-82 updates RSS · CI watch RSS
- Ochsner Health System portfolio CI